Manipulation of cytokine levels using CD83 gene products
First Claim
Patent Images
1. An antibody that can bind to a CD83 polypeptide of SEQ ID NO:
- 9, wherein activated CD4+ T-cells produce lower levels of interleukin-4 when said T-cells are contacted with the antibody, wherein said antibody comprises a light chain sequence set forth in SEQ ID NO;
15 and a heavy chain-sequence.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention provides methods for modulating cytokine levels, GM-CSF levels and the immune system using CD83 nucleic acids, CD83 polypeptides, anti-CD83 antibodies and factors that influence CD83 activity or expression. The invention also provides mice having a mutant CD83 gene and mice having a transgenic CD83 gene, which are useful for defining the role of CD83 in the immune system and for identifying compounds that can modulate CD83 and the immune system.
4 Citations
30 Claims
-
1. An antibody that can bind to a CD83 polypeptide of SEQ ID NO:
- 9, wherein activated CD4+ T-cells produce lower levels of interleukin-4 when said T-cells are contacted with the antibody, wherein said antibody comprises a light chain sequence set forth in SEQ ID NO;
15 and a heavy chain-sequence. - View Dependent Claims (2, 3, 4, 5)
- 9, wherein activated CD4+ T-cells produce lower levels of interleukin-4 when said T-cells are contacted with the antibody, wherein said antibody comprises a light chain sequence set forth in SEQ ID NO;
-
6. An antibody that can bind to a CD83 polypeptide of SEQ ID NO:
- 9, wherein CD4+ T-cell proliferation is decreased when said T-cells are contacted with the antibody, wherein said antibody comprises a light chain sequence set forth in SEQ ID NO;
15 and a heavy chain sequence. - View Dependent Claims (7, 8, 9, 10)
- 9, wherein CD4+ T-cell proliferation is decreased when said T-cells are contacted with the antibody, wherein said antibody comprises a light chain sequence set forth in SEQ ID NO;
-
11. An antibody that decreases the activity or expression of a CD83 polypeptide of SEQ ID NO:
- 9, wherein said antibody comprises a light chain sequence set forth in SEQ ID NO;
15 and a heavy chain-sequence. - View Dependent Claims (12, 13, 14, 15)
- 9, wherein said antibody comprises a light chain sequence set forth in SEQ ID NO;
-
16. An antibody that can bind to a CD83 polypeptide of SEQ ID NO:
- 9, wherein activated CD4+ T-cells produce lower levels of interleukin-4 when said T-cells are contacted with the antibody, wherein said antibody comprises a heavy chain sequence set forth in SEQ ID NO;
17 and a light chain-sequence. - View Dependent Claims (17, 18, 19, 20)
- 9, wherein activated CD4+ T-cells produce lower levels of interleukin-4 when said T-cells are contacted with the antibody, wherein said antibody comprises a heavy chain sequence set forth in SEQ ID NO;
-
21. An antibody that can bind to a CD83 polypeptide of SEQ ID NO:
- 9, wherein CD4+ T-cell proliferation is decreased when said T-cells are contacted with the antibody, wherein said antibody comprises a heavy chain sequence set forth in SEQ ID NO;
17 and a light chain sequence. - View Dependent Claims (22, 23, 24, 25)
- 9, wherein CD4+ T-cell proliferation is decreased when said T-cells are contacted with the antibody, wherein said antibody comprises a heavy chain sequence set forth in SEQ ID NO;
-
26. An antibody that decreases the activity or expression of a CD83 polypeptide of SEQ ID NO:
- 9, wherein said antibody comprises a heavy chain sequence set forth in SEQ ID NO;
17 and a light chain-sequence. - View Dependent Claims (27, 28, 29, 30)
- 9, wherein said antibody comprises a heavy chain sequence set forth in SEQ ID NO;
Specification